<DOC>
	<DOCNO>NCT00045877</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness combination therapy Proleukin Rituxan patient low-grade Non-Hodgkin 's Lymphoma previously fail Rituxan treatment .</brief_summary>
	<brief_title>Proleukin Combination With Rituxan Patients With Low-Grade Non-Hodgkin 's Lymphoma Who Have Previously Failed Rituxan Treatments</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosis disease status : Subjects CD20+ , Bcell , NonHodgkin 's lymphoma lowgrade follicular histology measurable relapse unresponsive disease prior therapy ; mantle cell chronic lymphocytic leukemia subtypes exclude . Subjects previously receive singleagent course rituximab show tumor response , response last &lt; 6 month . The previously administer rituximab must include least 75 % standard 4week regimen ( 4 x 375 mg/m2 ) . A record previous rituximab treatment response must available source document site . Exclusion : Subjects show tumor response response last &lt; 6 month treatment Rituximab combination Chemotherapy another therapeutic modality ( radiation radioimmunoconjugates ) . HIV positive . Symptomatic thyroid disease require medical intervention replacement treatment hypothyroidism . Clinically significant cardiac , pulmonary , /or hepatic dysfunction ( subject history congestive heart failure myocardial infarction , must stable least 6 month , current symptom If cardiac ejection fraction measure , must great 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Low-Grade Follicular Non-Hodgkin 's Lymphoma</keyword>
</DOC>